Patent: 7,084,118
✉ Email this page to a colleague
Summary for Patent: 7,084,118
| Title: | Combination treatment with t-PA variant and low molecular weight heparin |
| Abstract: | The invention concerns an improved therapeutic regimen for the treatment of thrombolytic disorders, such as acute myocardial infarction (AMI). In particular, the present invention concerns the treatment of thrombolytic disorders, e.g. AMI, with a combination of a tissue plasminogen activator (t-PA) variant having improved fibrin specificity and extended plasma half-life when compared with wild-type human t-PA and a low molecular weight heparin. |
| Inventor(s): | Armstrong; Paul (Edmonton, CA), Barron; Hal (San Francisco, CA), Berioli; Silvano (Perugia, IT), Bigonzi; Frederique (1\'Hay les Roses, FR), Bluhmki; Erich (Schwendi, DE), Chin; Richard (San Francisco, CA), Granger; Christopher (Durham, NC), Van De Werf; Frans (Herent, BE), Wang-Clow; Fong (Los Altos Hills, CA) |
| Assignee: | Genentech, Inc. (South San Francisco, CA) Boehringer Ingelheim Pharmaceuticals, Inc. (Ridgefield, CT) Aventis Pharma, S.A. (Antony, FR) Boehringer Ingelheim Pharma KG (Ingelheim/Rhein, DE) |
| Application Number: | 10/371,778 |
| Patent Claims: | see list of patent claims |
Details for Patent 7,084,118
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Genentech, Inc. | TNKASE | tenecteplase | For Injection | 103909 | 06/02/2000 | ⤷ Try a Trial | 2022-02-22 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
